Vertex Pharmaceuticals director Sangeeta N. Bhatia sold 271 shares of common stock at $547.86 per share, a total of $148,470, according to a Form 4 filing with the Securities and Exchange Commission on November 18, 2026. The transaction occurred on November 16, 2026.
The filing says the sale was made under a Rule 10b5-1 trading plan that Bhatia established on August 13, 2026. After the sale, Bhatia directly holds 4,653 shares.
The source reports that Vertex shares were trading near their 52-week high of $568.67 at the time, and that the stock rose 27% over the past year. The company has a market capitalization of $136 billion and a P/E ratio of 34.63, according to the report.
The report also notes that Vertex reported third-quarter 2026 results with cystic fibrosis revenue of $3.27 billion, close to the consensus estimate of $3.3 billion. Non-GAAP earnings per share of $4.76 slightly missed the consensus estimate of $4.82. Following the results, Stifel, Cantor Fitzgerald, Wells Fargo, JPMorgan and TD Cowen adjusted their price targets, with Stifel setting $563 with a Hold rating, Cantor Fitzgerald $619, Wells Fargo $650, JPMorgan $570 and TD Cowen $575.